Contrast Enhanced MRI of the Prostate

Prostate cancer detection and disease progression monitoring relies on systematic multi-core biopsies. Minimal invasive imaging capacities for lesion targeting and monitoring are badly needed. The purpose of this study is to determine if a new MRI technique can identify and monitor prostate disease progression. If so biopsy core number can be reduced to as small as one, and frequency for biopsy repeat can be reduced. The new technique is about a new way of analyzing the pictures taken as part of prostate MRI exam. This part is called dynamic contrast-enhanced MRI. It involves an injection of contrast reagent (or dye) through the arm vein during a time period when prostate MRI pictures are continuously taken.

Sex

Male

Minimum age

18 Years

Maximum age

75 Years

Inclusion Criteria:

* Men, age \>18 years.
* Any patient scheduled for prostate biopsy repeat or radical prostatectomy.
* Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

* Patients who would be normally excluded from undergoing an MRI examination - patients with a pacemaker, aneurysm clip or any other condition that would warrant avoidance of a strong magnetic field.
* Patients who are unable to cooperate for an MRI exam.
* Major surgery within a month of enrollment.
* Prostate biopsy six weeks prior to enrollment.
* Subject-reported reaction to gadolinium contrast reagent.